Erythropoietin accelerates tumor growth through increase of erythropoietin receptor (EpoR) as well as by the stimulation of angiogenesis in DLD-1 and Ht-29 xenografts

Molecular and Cellular Biochemistry

Volumn 421, Issue 1-2, 2016, Pages 1-18

  Tankiewicz Kwedlo, A ^a   Hermanowicz, J ^a   Surazynski A ^a   Rozkiewicz D ^a   Pryczynicz, A ^a   Domaniewski, T ^a   Pawlak, K ^a   Kemona, A ^a   Pawlak, D ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Colon cancer; Erythropoietin; Erythropoietin receptor; Vascular endothelial growth factor receptor

Indexed keywords

CD31 ANTIGEN; ERYTHROPOIETIN RECEPTOR; MESSENGER RNA; PROTEIN KINASE B; RECOMBINANT ERYTHROPOIETIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; EPO PROTEIN, HUMAN; ERYTHROPOIETIN; TUMOR PROTEIN;

ADENOCARCINOMA CELL LINE; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL COUNT; CELL COUNTER; CELL CULTURE; CELL PROLIFERATION; COLON ADENOCARCINOMA; COLON CARCINOGENESIS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; CANCER TRANSPLANTATION; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TUMOR CELL LINE; VASCULARIZATION; XENOGRAFT;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; ERYTHROPOIETIN; HETEROGRAFTS; HUMANS; MICE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, ERYTHROPOIETIN;

EID: 84982253641     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-016-2779-x     Document Type: Article

References (45)

1. Richmond TD, Chohan M, Barber DL (2005) Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol 15:146–455
2. Alexiusdottir KK, Möller PH, Snaebjornsson P et al (2012) Association of symptoms of colon cancer patients with tumor location and TNM tumor stage. Scand J Gastroenterol 47:795–801
3. Hardee ME, Kirkpatrick JP, Shan S et al (2005) Human recombinant erythropoietin (Epo) has no effect on tumour growth or angiogenesis. Br J Cancer 93:1350–1355
4. LaMontagne KR, Butler J, Marshall DJ et al (2006) Recombinant Epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther 5:347–355
5. Hardee ME, Cao Y, Fu P et al (2007) Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS One 2:e549
6. Yasuda Y, Fujita Y, Matsuo T et al (2003) Erythropoietin regulates tumour growth of human malignancies. Carcinogenesis 24:1021–1029
7. Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ (2008) The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 67:39–61
8. Acs G, Acs P, Beckwith SM et al (2001) Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 61:3561–3565
9. Yasuda Y, Masuda S, Chikuma M, Inoue K, Nagao M, Sasaki R (1998) Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis. J Biol Chem 273:25381–25387
10. Ribatti D, Marzullo A, Gentile A et al (2007) Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma. Histopathology 50:591–596
11. Ogilvie M, Yu X, Nicolas-Metral V et al (2000) Erythropoietin stimulates proliferation and interferes with differentiation of myoblasts. J Biol Chem 275:39754–39761
12. Gombos Z, Danihel L, Repiska V, Acs G, Furth E (2011) Expression of erythropoietin and its receptor increases in colonic neoplastic progression: the role of hypoxia in tumorigenesis. Indian J Pathol Microbiol 54:273–278
13. Lindgren G, Ekblad L, Vallon-Christersson J, Kjellén E, Gebre-Medhin M, Wennerberg J (2014) Erythropoietin suppresses the activation of pro-apoptotic genes in head and neck squamous cell carcinoma xenografts exposed to surgical trauma. BMC Cancer 14:648
14. Carlini RG, Alonzo EJ, Dominguez J et al (1999) Effect of recombinant human erythropoietin on endothelial cell apoptosis. Kidney Int 55:546–553
15. Nagai A, Nakagawa E, Choi HB, Hatori K, Kobayashi S, Kim SU (2001) Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol 60:386–392
16. Todaro M, Turdo A, Bartucci M et al (2013) Erythropoietin activates cell survival pathways in breast cancer stem-like cells to protect them from chemotherapy. Cancer Res 73:6393–6400
17. Pascual M, Bohle B, Alonso S et al (2013) Preoperative administration of erythropoietin stimulates tumor recurrence after surgical excision of colon cancer in mice by a vascular endothelial growth factor-independent mechanism. J Surg Res 183:270–277
18. Leyland-Jones B, Semiglazov V, Pawlicki M et al (2005) Maintaining normal hemoglobin levels with Epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23:5960–5972
19. Henke M, Laszig R, Rübe C et al (2003) Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362:1255–1260
20. Wright JR, Ung YC, Julian JA et al (2007) Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25:1027–1032
21. Tankiewicz-Kwedlo A, Pawlak D, Domaniewski T, Buczko W (2010) Effect of erythropoietin, 5 fluorouracil and SN-38 on the growth of DLD-1 cells. Pharmacol Rep 62:926–937
22. Elliott S, Busse L, Swift S et al (2012) Lack of expression and function of erythropoietin receptors in the kidney. Nephrol Dial Transplant 27:2733–2745
23. Balleari E, Clavio M, Arboscello E et al (2011) Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes. Leuk Res 35:1472–1476
24. Feldman L, Wang Y, Rhim JS, Bhattacharya N, Loda M, Sytkowski AJ (2006) Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells. Prostate 66:135–145
25. Westenfelder C, Baranowski RL (2000) Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 58:647–657
26. Shinohara N, Tsuduki T, Ito J et al (2012) Jacaric acid, a linolenic acid isomer with a conjugated triene system, has a strong antitumor effect in vitro and in vivo. Biochim Biophys Acta 1821:980–988
27. Feldman JP, Goldwasser R, Mark S, Schwartz J, Orion I (2009) A mathematical model for tumor volume evaluation using two-dimensions. JAQM 4:455–462
28. Sinclair AM, Todd MD, Forsythe K, Knox SJ, Elliott S, Begley CG (2007) Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 110:477–488
29. Ghanem MA, van Steenbrugge GJ, Sudaryo MK, Mathoera RB, Nijman JM, van der Kwast TH (2003) Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma. J Clin Pathol 56:107–113
30. Franke TF (2008) PI3K/Akt: getting it right matters. Oncogene 27:6473–6488
31. Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC (2002) Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10:151–162
32. Liu Q, Qiu J, Liang M, Golinski J et al (2014) Akt and mTOR mediate programmed necrosis in neurons. Cell Death Dis 5:e1084
33. Batra S, Perelman N, Luck LR, Shimada H, Malik P (2003) Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Investig 83:1477–1487
34. Trincavelli ML, Da Pozzo E, Ciampi O et al (2013) Regulation of erythropoietin receptor activity in endothelial cells by different erythropoietin (epo) derivatives: an in vitro study. Int J Mol Sci 14:2258–2281
35. Swift S, Ellison AR, Kassner P et al (2010) Absence of functional EpoR expression in human tumor cell lines. Blood 115:4254–4263
36. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW (2006) Erythropoietin biology in cancer. Clin Cancer Res 12:332–339
37. Mulcahy L (2001) The erythropoietin receptor. Semin Oncol 28:19–23
38. Lopez TV, Lappin TR, Maxwell P et al (2011) Autocrine/paracrine erythropoietin signalling promotes JAK/STAT-dependent proliferation of human cervical cancer cells. Int J Cancer 129:2566–2576
39. Shi Z, Hodges VM, Dunlop EA et al (2010) Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line. Mol Cancer Res 8:615–626
40. Nangaku M (2013) Tissue protection by erythropoietin: new findings in a moving field. Kidney Int 84:427–429
41. Rozengurt E, Soares HP, Sinnet-Smith J (2014) Suppression of feedback loops mediated by PI3K/mTOR induces multiple overactivation of compensatory pathways: an unintended consequence leading to drug resistance. Mol Cancer Ther 13:2477–2488
42. Arcasoy MO, Amin K, Karayal AF et al (2002) Functional significance of erythropoietin receptor expression in breast cancer. Lab Investig 82:911–918
43. Yasuda Y, Fujita Y, Masuda S et al (2002) Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs. Carcinogenesis 23:1797–1805
44. Jaquet K (2002) Eryhropoietin and VEGF exhibit angiogenic potential. Microvasc Res 64:326–333
45. Cao G, O’Brien CD, Zhou Z et al (2001) Involvement of human PECAM-1 in angiogenesis and in vitro endothelial cell migration. Am J Physiol Cell Physiol 282:C1181–C1190